<DOC>
	<DOCNO>NCT02916485</DOCNO>
	<brief_summary>Assessment clinical performance safety Magmaris Sirolimus-Eluting Resorbable Coronary Magnesium Scaffold cohort patient India de novo coronary artery lesion .</brief_summary>
	<brief_title>Safety Clinical Performance Sirolimus-eluting Absorbable Metal Scaffold</brief_title>
	<detailed_description>This prospective , multi-centre , single-arm , open label trial ass safety clinical performance Magmaris Drug Eluting Absorbable Metal Scaffold . A total 110 patient de novo lesion native coronary artery enrol 8 investigational site India . In-hospital clinical follow-up visit take place 1 6 month post procedure . The primary endpoint target lesion failure ( composite cardiac death , target vessel Q-wave non-Q wave myocardial infarction , coronary artery bypass grafting , clinically drive target lesion revascularization ) 1 month post procedure .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>1 . Subject ≥ 18 year ≤ 80 year age 2 . Written subject informed consent available prior percutaneous coronary intervention ( PCI ) . Remark : Vulnerable subject may enrol trial 3 . Subject stable unstable angina pectoris document silent ischemia 4 . Subject eligible PCI 5 . Subject acceptable candidate coronary artery bypass surgery 6 . Subject maximum two single de novo lesion two different major epicardial vessel 7 . Reference vessel diameter 2.73.7 mm visual estimation , depend scaffold size use 8 . Target lesion length ≤ 21 mm visual estimation , depend scaffold size use 9 . Target lesion stenosis visual estimation ≥ 50 % &lt; 100 % TIMI flow ≥1 10 . Eligible Dual Anti Platelet Therapy ( DAPT ) 1 . Pregnant breastfeeding female females intend become pregnant time study 2 . Subject clinical symptom and/or electrocardiogram ( ECG ) change consistent acute ST elevation myocardial infarction ( STEMI ) within 72 hour prior index procedure . Note : Hemodynamically stable nonSTEMI ( NSTEMI ) subject eligible study enrollment 3 . Subjects ≥2 fold CK level absence CK ≥3 fold CKMB level upper range limit within 24 hour prior index procedure 4 . Left main coronary artery disease 5 . Threevessel coronary artery disease time procedure 6 . Thrombus target vessel 7 . Subject currently participate another study investigational device investigational drug reach primary endpoint yet 8 . Planned interventional treatment nontarget vessel within 30 day postprocedure 9 . Subject dialysis 10 . Planned intervention target vessel index procedure 11 . Ostial target lesion ( within 3.0 mm vessel origin ) 12 . Target lesion involves side branch &gt; 2.0 mm diameter 13 . Documented leave ventricular ejection fraction ( LVEF ) ≤ 30 % 14 . Heavily calcified lesion 15 . Target lesion locate supply arterial venous bypass graft 16 . The target lesion require treatment device predilatation balloon prior Magmaris study device placement ( include limit directional coronary atherectomy , excimer laser , rotational atherectomy , etc . ) 17 . Unsuccessful predilatation , define minimal lumen diameter small respective crossing profile Magmaris study device angiographic complication ( e.g . distal embolization , side branch closure , extensive dissection ca n't cover single scaffold ) , visual estimation 18 . Known allergy : Acetylsalicylic Acid ( ASA ) , Heparin , contrast medium , Sirolimus , Everolimus similar drug ( i.e. , ABT 578 , Biolimus , Tacrolimus ) , PLLA , Silicon Carbide , Magnesium , Yttrium , Neodymium , Zirconium , Gadolinium , Dysprosium , Tantalum 19 . Impaired renal function ( serum creatinine &gt; 2.5 mg/dl 221 µmol/l ) determine within 72 hour prior index procedure 20 . Subject receive oral intravenous immunosuppressive therapy ( inhaled steroid exclude ) know life limit immunosuppressive autoimmune disease ( e.g. , human immunodeficiency virus , systemic lupus erythematosus , include diabetes mellitus ) 21 . Proximal distal target lesion locate stenosis might require future revascularization impede run detect diagnostic angiography 22 . Life expectancy le 6 month 23 . Planned surgery dental surgical procedure within 6 month index procedure 24 . Subject tortuous vessel may impair scaffold placement region obstruction proximal lesion 25 . In investigator opinion subject able comply followup requirement .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>bioresorbable scaffold</keyword>
	<keyword>vascular restoration therapy</keyword>
</DOC>